文献速递肺外科

外周临床T1a N0非小细胞肺癌淋巴结转移的临床预测因素

Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2017-05-24

本研究回顾性分析449例外周临床T1a N0非小细胞肺癌患者,均经PET/CT评估为淋巴结阴性。结果显示9.6%患者术后病理证实淋巴结转移,PET-SUVmax>3.3是唯一独立预测因素,提示高SUVmax患者需进一步诊断分期。

要点

  • 外周临床T1a N0非小细胞肺癌病理淋巴结转移率为9.6%。
  • PET-SUVmax>3.3是N1/N2转移唯一独立预测因素。
  • 高SUVmax患者考虑楔形切除或SBRT前需进一步分期。

核心结论

  • 原发肿瘤高PET-SUVmax与外周T1a N0非小细胞肺癌淋巴结转移风险升高相关。

研究设计与样本

  • 回顾性分析前瞻性数据库(2000至2015年),共1342例临床T1a N0非小细胞肺癌患者,其中914例(68%)接受肺叶切除术;最终纳入449例外周型、PET/CT判断淋巴结阴性的患者。

主要发现

  • 449例患者中9.6%(43/449)发现淋巴结转移,其中pN1占4.5%(20例),pN2占5.1%(23例)。
  • PET-SUVmax预测淋巴结转移的ROC曲线截断值为3.3。
  • 多因素分析显示PET-SUVmax>3.3是N1/N2转移的唯一独立预测因素(p=0.016)。
  • 淋巴结转移患者无病生存呈较差趋势(p=0.068)。

关键数值与推荐

  • PET-SUVmax截断值3.3用于预测淋巴结转移。
  • PET-SUVmax>3.3为N1/N2转移独立预测因素(p=0.016)。

临床怎么用

  • 对外周临床T1a N0且PET-SUVmax>3.3的非小细胞肺癌患者,应考虑进一步诊断分期如支气管内超声。
  • 尤其计划行楔形切除或立体定向体部放疗前,需评估淋巴结转移风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the relatively high sensitivity of fluorodeoxyglucose-positron emission tomography (PET) and computed tomography (CT) scans used for staging of non-small cell lung cancer (NSCLC), a subset of patients with peripherally located clinical T1a N0 will be upstaged due to pathologic nodal disease. It is important to study this risk of upstaging, especially if local treatments, such as wedge resection or stereotactic body radiation therapy, are potential treatment modalities. Our aim was to determine the rate of pathologic N1/N2 disease in peripherally located clinical T1a N0 NSCLC and predictive factors for nodal metastasis. METHODS: A retrospective review of a prospective database (2000 to 2015) identified 1,342 patients with clinical T1a N0 NSCLC, and 914 (68%) underwent lobectomy. Among this group, 449 patients had peripherally located tumors and were deemed node negative by fluorodeoxyglucose-PET/CT scan. The relationship between clinicopathologic features and the PET maximal-standardized uptake value (SUVmax) of the primary tumor was investigated. Predictors for nodal metastasis were determined by multivariable logistic regression analysis. The receiver operating characteristic curve was used to assess the cutoff value of PET-SUVmax on the incidence of nodal metastasis. RESULTS: Nodal metastasis was detected in 9.6% (43 of 449) of the patients: 4.5% (n = 20) had pN1 and 5.1% (n = 23) had pN2 metastasis. The relationship between SUVmax and development of pathologic nodal metastasis was calculated using the receiver operating characteristic curve with cutoff point at SUVmax of 3.3. In multivariable analysis, PET-SUVmax exceeding 3.3 was the only independent predictor for N1/N2 metastasis (p = 0.016). Disease-free survival showed a trend of poor survival for patients with nodal metastasis (p = 0.068). CONCLUSIONS: High PET-SUVmax of the primary tumor is associated with elevated risk of nodal disease for peripheral T1a N0 NSCLC patients. Further diagnostic procedures, such as endobronchial ultrasound, may be required, especially if wedge resection or stereotactic body radiation therapy are being considered.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Ghaly G, Rahouma M, Kamel MK, et al. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer. Ann Thorac Surg. 2017. PMID: 28551047. doi:10.1016/j.athoracsur.2017.02.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。